Open AccessArrhythmogenic right ventricular cardiomyopathy/dysplasia ( ARVC /D) in clinical practice
Author(s) -
Li Ka Hou Christien,
Bazoukis George,
Liu Tong,
Li Guangping,
Wu William K. K.,
Wong Sunny Hei,
Wong Wing Tak,
Chan Yat Sun,
Wong Martin C. S.,
Wassilew Katharina,
Vassiliou Vassilios S.,
Tse Gary
Publication year - 2018
Publication title -
journal of arrhythmia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 21
eISSN - 1883-2148
pISSN - 1880-4276
DOI - 10.1002/joa3.12021
Subject(s) - medicine , cardiology , sudden cardiac death , arrhythmogenic right ventricular dysplasia , cardiomyopathy , hypertrophic cardiomyopathy , dysplasia , disease , sudden death , population , heart failure , environmental health
Abstract Arrhythmogenic right ventricular cardiomyopathy/dysplasia ( ARVC /D) is an inherited myocardial disease characterized by fibro‐fatty replacement of the right ventricular myocardium, and associated with paroxysmal ventricular arrhythmias and sudden cardiac death ( SCD ). It is currently the second most common cause of SCD after hypertrophic cardiomyopathy in young people <35 years of age, causing up to 20% of deaths in this patient population. This condition has a male preponderance and is more commonly found in individuals of Italian and Greek descent. To date, there is no single diagnostic test for ARVC /D and the diagnosis is made based on clinical, electrocardiographic, and radiological findings according to the Revised 2010 Task Force Criteria. In this review, we will discuss the mainstay treatment which includes pharmacotherapy, implantable cardioverter‐defibrillator insertion for abortion of sudden cardiac death, and in the advanced stages of the disease cardiac transplantation.